Overview

A Study of CIN-107 in Patients With Uncontrolled Hypertension Receiving 1 Antihypertensive Agent

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose strengths of CIN-107 in the treatment of patients with uncontrolled hypertension who are currently taking 1 anti-hypertensive medication
Phase:
Phase 2
Details
Lead Sponsor:
CinCor Pharma, Inc.
Collaborator:
CinRx